-
Je něco špatně v tomto záznamu ?
Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
JC. Ianotto, N. Curto-Garcia, M. Lauermanova, D. Radia, JJ. Kiladjian, CN. Harrison,
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, systematický přehled
NLK
Directory of Open Access Journals
od 1994
Free Medical Journals
od 1994
Freely Accessible Science Journals
od 1994
PubMed Central
od 2009
Europe PubMed Central
od 2009
Open Access Digital Library
od 1994-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
- MeSH
- asymptomatické nemoci MeSH
- časná diagnóza MeSH
- cytotoxiny terapeutické užití MeSH
- dítě MeSH
- esenciální trombocytemie diagnóza farmakoterapie genetika patologie MeSH
- exprese genu MeSH
- fibrinolytika terapeutické užití MeSH
- Janus kinasa 1 genetika MeSH
- Janus kinasa 2 genetika MeSH
- krvácení diagnóza farmakoterapie genetika patologie MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mutace MeSH
- polycythaemia vera diagnóza farmakoterapie genetika patologie MeSH
- prognóza MeSH
- splenomegalie diagnóza farmakoterapie genetika patologie MeSH
- trombóza diagnóza farmakoterapie genetika patologie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children and young adults. We therefore performed a systematic review of cases, published since 2005, concerning patients aged below 20 years at the time of diagnosis of essential thrombocythemia or polycythemia vera. We identified 396 cases of essential thrombocythemia and 75 of polycythemia vera. The median age at diagnosis was 9.3 and 12 years, respectively, and females constituted 57.6% and 45% of the groups, respectively. Half of the patients were asymptomatic at diagnosis. The proportion of so-called triple negativity was high: 57% in essential thrombocythemia and 73% in polycythemia vera. The incidence of thrombosis during the follow-up was 9.3% in patients with polycythemia vera and less, 3.8%, in those with essential thrombocythemia. Venous events were predominant (84.2%), with hemorrhagic episodes being rarer (<5%). The risk of evolution also seemed low (2% to myelofibrosis and no reports of acute leukemia), but the median follow-up was only 50 months. Survival curves were not available. Half of the patients received an antithrombotic drug and 40.5% received a cytoreductive drug. All data should be analyzed with care because of the proportion of missing data (10.7% to 74.7%). This review highlights interesting points concerning this population of young patients with myeloproliferative neoplasms, including that such patients were identified as negative for all common driver mutations, but also shows the need for larger contemporary cohorts with longer follow-up to assess the true prognosis of these patients.
Centre d'Investigation Clinique Hôpital St Louis Paris France
Department of Haematology Guy's and St Thomas' NHS Trust London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023766
- 003
- CZ-PrNML
- 005
- 20201214131116.0
- 007
- ta
- 008
- 201125s2019 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3324/haematol.2018.200832 $2 doi
- 035 __
- $a (PubMed)30679326
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Ianotto, Jean-Christophe $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK. Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.
- 245 10
- $a Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review / $c JC. Ianotto, N. Curto-Garcia, M. Lauermanova, D. Radia, JJ. Kiladjian, CN. Harrison,
- 520 9_
- $a Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children and young adults. We therefore performed a systematic review of cases, published since 2005, concerning patients aged below 20 years at the time of diagnosis of essential thrombocythemia or polycythemia vera. We identified 396 cases of essential thrombocythemia and 75 of polycythemia vera. The median age at diagnosis was 9.3 and 12 years, respectively, and females constituted 57.6% and 45% of the groups, respectively. Half of the patients were asymptomatic at diagnosis. The proportion of so-called triple negativity was high: 57% in essential thrombocythemia and 73% in polycythemia vera. The incidence of thrombosis during the follow-up was 9.3% in patients with polycythemia vera and less, 3.8%, in those with essential thrombocythemia. Venous events were predominant (84.2%), with hemorrhagic episodes being rarer (<5%). The risk of evolution also seemed low (2% to myelofibrosis and no reports of acute leukemia), but the median follow-up was only 50 months. Survival curves were not available. Half of the patients received an antithrombotic drug and 40.5% received a cytoreductive drug. All data should be analyzed with care because of the proportion of missing data (10.7% to 74.7%). This review highlights interesting points concerning this population of young patients with myeloproliferative neoplasms, including that such patients were identified as negative for all common driver mutations, but also shows the need for larger contemporary cohorts with longer follow-up to assess the true prognosis of these patients.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a asymptomatické nemoci $7 D058070
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a cytotoxiny $x terapeutické užití $7 D003603
- 650 _2
- $a časná diagnóza $7 D042241
- 650 _2
- $a fibrinolytika $x terapeutické užití $7 D005343
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a krvácení $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Janus kinasa 1 $x genetika $7 D053613
- 650 _2
- $a Janus kinasa 2 $x genetika $7 D053614
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a polycythaemia vera $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D011087
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a splenomegalie $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D013163
- 650 _2
- $a esenciální trombocytemie $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D013920
- 650 _2
- $a trombóza $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D013927
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Curto-Garcia, Natalia $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK.
- 700 1_
- $a Lauermanova, Marie $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK. Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Radia, Deepti $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK.
- 700 1_
- $a Kiladjian, Jean-Jacques $u Centre d'Investigation Clinique, Hôpital St Louis, Paris, France.
- 700 1_
- $a Harrison, Claire N $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK claire.harrison@gstt.nhs.uk.
- 773 0_
- $w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 8 (2019), s. 1580-1588
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30679326 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131114 $b ABA008
- 999 __
- $a ok $b bmc $g 1596085 $s 1114442
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 104 $c 8 $d 1580-1588 $e 20190124 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
- LZP __
- $a Pubmed-20201125